198 related articles for article (PubMed ID: 16699457)
1. Patient-reported gastrointestinal symptom burden and health-related quality of life following conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium.
Chan L; Mulgaonkar S; Walker R; Arns W; Ambühl P; Schiavelli R
Transplantation; 2006 May; 81(9):1290-7. PubMed ID: 16699457
[TBL] [Abstract][Full Text] [Related]
2. Improvement in gastrointestinal and health-related quality of life outcomes after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in liver transplant recipients.
Sterneck M; Settmacher U; Ganten T; Sarrazin C; Speidel N; Broering D; Heyne N; Paulus E; Mertens M; Fischer L
Transplant Proc; 2014; 46(1):234-40. PubMed ID: 24507058
[TBL] [Abstract][Full Text] [Related]
3. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in renal transplant recipients with gastrointestinal tract disorders.
Darji P; Vijayaraghavan R; Thiagarajan CM; Sharma RK; Subbarao B; Pishardy R; Dakshinamurthy KV; Vijaykumar R; Abraham G; Bhaskar S; Agarwal L; Shah B; Abraham A; John M; Sampathkumar K; Das T; Umesh L; Sundar S; Ballal H; Jasuja S; Saxena S; Saha TK
Transplant Proc; 2008 Sep; 40(7):2262-7. PubMed ID: 18790208
[TBL] [Abstract][Full Text] [Related]
4. Improved gastrointestinal symptoms and quality of life after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in renal transplant patients receiving tacrolimus.
Hwang HS; Hyoung BJ; Kim S; Oh HY; Kim YS; Kim JK; Kim YH; Kim YL; Kim CD; Shin GT; Yang CW
J Korean Med Sci; 2010 Dec; 25(12):1759-65. PubMed ID: 21165291
[TBL] [Abstract][Full Text] [Related]
5. Gastrointestinal quality of life improvement of renal transplant recipients converted from mycophenolate mofetil to enteric-coated mycophenolate sodium drugs or agents: mycophenolate mofetil and enteric-coated mycophenolate sodium.
Ortega F; Sánchez-Fructuoso A; Cruzado JM; Gómez-Alamillo JC; Alarcón A; Pallardó L; Morales JM; Oliver J; Guinea G;
Transplantation; 2011 Aug; 92(4):426-32. PubMed ID: 21760569
[TBL] [Abstract][Full Text] [Related]
6. Improvement of gastrointestinal symptoms after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in liver transplant patients.
Toledo AH; Hendrix L; Buchholz V; Fisher E; Newton K; Smith C; Gerber DA
Clin Transplant; 2012; 26(1):156-63. PubMed ID: 21470310
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of tolerability and ability to increase immunosuppression in renal transplant patients converted from mycophenolate mofetil to enteric-coated mycophenolate sodium.
Bilodeau JF; Montambault P; Wolff JL; Lemire J; Masse M
Transplant Proc; 2009 Nov; 41(9):3683-9. PubMed ID: 19917367
[TBL] [Abstract][Full Text] [Related]
8. Quality of life in renal transplant recipients following conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium.
Cofan F; Rosich E; Arias M; Torregrosa V; Oppenheimer F; Campistol JM
Transplant Proc; 2007 Sep; 39(7):2179-81. PubMed ID: 17889130
[TBL] [Abstract][Full Text] [Related]
9. Enteric-coated mycophenolate sodium versus mycophenolate mofetil in renal transplant recipients experiencing gastrointestinal intolerance: a multicenter, double-blind, randomized study.
Langone AJ; Chan L; Bolin P; Cooper M
Transplantation; 2011 Feb; 91(4):470-8. PubMed ID: 21245794
[TBL] [Abstract][Full Text] [Related]
10. Improvement in 3-month patient-reported gastrointestinal symptoms after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in renal transplant patients.
Bolin P; Tanriover B; Zibari GB; Lynn ML; Pirsch JD; Chan L; Cooper M; Langone AJ; Tomlanovich SJ
Transplantation; 2007 Dec; 84(11):1443-51. PubMed ID: 18091520
[TBL] [Abstract][Full Text] [Related]
11. Gastrointestinal side effects in liver transplant recipients taking enteric-coated mycophenolate sodium vs. mycophenolate mofetil.
Lopez-Solis R; DeVera M; Steel J; Fedorek S; Sturdevant M; Hughes C; Humar A
Clin Transplant; 2014 Jul; 28(7):783-8. PubMed ID: 24754682
[TBL] [Abstract][Full Text] [Related]
12. EC-MPS permits lower gastrointestinal symptom burden despite higher MPA exposure in patients with severe MMF-related gastrointestinal side-effects.
Sabbatini M; Capone D; Gallo R; Pisani A; Polichetti G; Tarantino G; Gentile A; Rotaia E; Federico S
Fundam Clin Pharmacol; 2009 Oct; 23(5):617-24. PubMed ID: 19656208
[TBL] [Abstract][Full Text] [Related]
13. Enteric-coated mycophenolate sodium: safe conversion from mycophenolate mofetil in maintenance renal transplant recipients.
Budde K; Glander P; Diekmann F; Dragun D; Waiser J; Fritsche L; Neumayer HH
Transplant Proc; 2004 Mar; 36(2 Suppl):524S-527S. PubMed ID: 15041401
[TBL] [Abstract][Full Text] [Related]
14. Changes in the small bowel of symptomatic kidney transplant recipients converted from mycophenolate mofetil to enteric-coated mycophenolate sodium.
Bunnapradist S; Sampaio MS; Wilkinson AH; Pham PT; Huang E; Kuo HT; Anastasi B; Danovitch GM; Lo SK
Am J Nephrol; 2014; 40(2):184-90. PubMed ID: 25196230
[TBL] [Abstract][Full Text] [Related]
15. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in stable maintenance renal transplant patients: pooled results from three international, multicenter studies.
Pietruck F; Abbud-Filho M; Vathsala A; Massari PU; Po-Huang L; Nashan B
Transplant Proc; 2007; 39(1):103-8. PubMed ID: 17275484
[TBL] [Abstract][Full Text] [Related]
16. Use of enteric-coated mycophenolate sodium in liver transplant patients with intestinal intolerance caused by mycophenolate mofetil.
Doria C; Ramirez CB; Frank AM; Vaccino S; Fraser N; Marino IR
Clin Transplant; 2009; 23(6):882-6. PubMed ID: 19573090
[TBL] [Abstract][Full Text] [Related]
17. Gastrointestinal (GI)-Specific patient reported outcomes instruments differentiate between renal transplant patients with or without GI symptoms: results from a South American cohort.
Machnicki G; Pefaur J; Gaite L; Linchenco AM; Raimondi C; Schiavelli R; Otero A; Margolis MK
Health Qual Life Outcomes; 2008 Jul; 6():53. PubMed ID: 18644133
[TBL] [Abstract][Full Text] [Related]
18. Effect of conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium on maximum tolerated dose and gastrointestinal symptoms following kidney transplantation.
Shehata M; Bhandari S; Venkat-Raman G; Moore R; D'Souza R; Riad H; Bakran A; Baker R; Needham C; Andrews C
Transpl Int; 2009 Aug; 22(8):821-30. PubMed ID: 19386081
[TBL] [Abstract][Full Text] [Related]
19. Safety assessment of the conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in stable renal transplant recipients.
Massari P; Duro-Garcia V; Girón F; Hernández E; Juárez F; Castro C; Toledo M;
Transplant Proc; 2005 Mar; 37(2):916-9. PubMed ID: 15848574
[TBL] [Abstract][Full Text] [Related]
20. Better mycophenolic acid 12-hour trough level after enteric-coated mycophenolate sodium in patients with gastrointestinal intolerance to mycophenolate mofetil.
Sánchez Fructuoso A; Calvo N; Moreno MA; Giorgi M; Conesa J; Barrientos A
Transplant Proc; 2007 Sep; 39(7):2194-6. PubMed ID: 17889135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]